Biologic agents including soluble receptors and monoclonal antibodies that block the action of a variety of cytokines including tumor necrosis alpha, interleukin-1, interleukin-6 have been used with variable success in Kawasaki disease[16-19], granulomatosis with polyangiitis (Wegener granulomatosis) [20,21] and other severe forms of vasculitis [22-28]. This evidence concerns the gene IL6 and granulomatosis with polyangiitis.